ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.
ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.
复制标题
DOI：
10.1002/0471142735.im2009s82
复制
发表时间：
2008-08-01
影响因子：
--
通讯作者：
Cavallo, Federica
中科院分区：
文献类型：
--
作者：
Quaglino, Elena;Mastini, Cristina;Cavallo, Federica
表皮生长因子受体属于受体酪氨酸激酶 (RTK) 超家族，其中包括 ErbB2。 ErbB2 参与正常的生理过程，如胚胎发生、细胞增殖、分化、粘附运动和细胞凋亡，而其功能障碍或过度表达则导致发育缺陷、糖尿病和癌症。 ErbB2 的人类直向同源物称为 Her-2（人 ErbB2），而大鼠直向同源物称为 neu（大鼠 ErbB2）。由于 ErbB2 直接参与致癌作用，因此大鼠 neu 癌基因转基因小鼠可以直接评估药物和疫苗抑制 neu 驱动的癌症进展的能力。来自该模型的信息可以提供类似治疗对患者的疗效的指示。该评论提供了有关使用这些转基因小鼠模型评估抗肿瘤策略功效的关键信息。
The epidermal growth factor receptor belongs to a superfamily of receptor tyrosine kinases (RTK) that includes ErbB2. ErbB2 is involved in normal physiological processes, such as embryogenesis, cell proliferation, differentiation, adhesion motility, and apoptosis, while its malfunction or overexpression is responsible for development defects, diabetes, and cancer. The human ortholog of ErbB2 is referred as Her-2 (human ErbB2) while the rat ortholog is referred as neu (rat ErbB2). As ErbB2 is directly involved in carcinogenesis, mice transgenic for the rat neu oncogene allow straightforward assessment of the ability of drugs and vaccines to inhibit the progression of neu-driven cancer. Information from this model may provide indications on the efficacy of similar treatments in patients. This commentary provides key information regarding the use of these transgenic mouse models for evaluation of the efficacy of anti-tumor strategies.